An interventional study of Mini-Pool IVIG in Persistent Immune Thrombocytopenia, sponsored by Assiut University. Recruiting at 3 sites in Egypt. Open to participants aged 1 Year to 10 Years. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Assiut University.
Among the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, this one is one of 3 that started in 2025, is one of 3 with no phase, and was the 13th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 18–60
Assiut University
Ages 18–60
Assiut University
Ages 18–65 · Healthy volunteers
Assiut University
Ages 18+
Assiut University
Ages up to 17
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 50 across the 6 interventional studies, 100 across the 9 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06137105Assiut UniversityThrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura | 2026-12 |
| NCT07182760Assiut UniversityUltrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia | 2027-05 |
| NCT07798050Assiut UniversitySelective Mediterranean Diet in Immune Thrombocytopenia | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer are:
Can mini-pool IVIG raise platelet levels in children with persistent ITP?
Can it reduce bleeding episodes and hospital visits?
What side effects, if any, are seen with this treatment?
There is no comparison group in this study. All participants will receive mini-pool IVIG, which is made from small pools of donated plasma using a cost-effective process.
Participants will:
Receive one dose of mini-pool IVIG through a vein over 6 to 8 hours
Receive follow-up doses every 2 to 4 weeks for up to 5 doses, based on their platelet count
Have regular blood tests and checkups during the study and for 6 months after treatment
Report on bleeding episodes, physical activity, school attendance, and side effects
Immune thrombocytopenia (ITP) is an autoimmune condition where the immune system destroys platelets, leading to low platelet counts and increased risk of bleeding. Persistent ITP is defined as ongoing thrombocytopenia lasting 3 to 12 months after initial diagnosis. Children with persistent ITP who lose their response to first-line treatments, such as steroids or standard intravenous immunoglobulin (IVIG), have limited therapeutic options, especially in low- and middle-income countries, due to the high cost of commercial IVIG preparations.
Mini-pool IVIG is produced from small pools of plasma collected locally, using a validated process with virus inactivation and IgG purification steps. This method enables safe, cost-effective preparation of IVIG in resource-limited settings. Prior research has shown that mini-pool IVIG is effective and well-tolerated in acute pediatric ITP, but its role as a second-line therapy for persistent ITP has not been evaluated.
This multicenter, prospective clinical trial will enroll 20 children aged 1 to 10 years with persistent ITP at three tertiary care pediatric hematology centers in Egypt. Participants will receive a loading dose of mini-pool IVIG at 1 g/kg, followed by maintenance doses of 0.5 g/kg every 2 to 4 weeks for up to five additional doses, with dose intervals adjusted based on platelet counts.
Throughout the study, participants will undergo regular blood counts, bleeding assessments using the Bleeding Assessment Tool (BAT), and monitoring for infusion-related or delayed adverse events. Data on school attendance, physical activity, and patient or family satisfaction will also be collected.
Responses to therapy will be classified as complete response (CR), response (R), or no response (NR) based on platelet count thresholds and bleeding status, with response duration measured from achievement of CR or R to loss of response. Participants achieving sustained response off therapy (SRoT) or response off therapy (RoT) during the 6-month post-treatment follow-up will be identified to evaluate durability of treatment effects.
This study aims to provide evidence on the safety and efficacy of mini-pool IVIG as a second-line therapy for persistent pediatric ITP, potentially offering an affordable and effective treatment alternative in settings where standard IVIG is inaccessible due to cost.
Inclusion Criteria:Age 1 - 10 years
Exclusion Criteria:-History of severe drug adverse events to IVIG
Participants in this arm will receive mini-pool intravenous immunoglobulin (IVIG) as second-line therapy for persistent immune thrombocytopenia (ITP). Treatment includes a loading dose of 1 g/kg infused over 6-8 hours, followed by maintenance doses of 0.5 g/kg given every 2 to 4 weeks for up to five additional doses. The dosing interval is adjusted based on each participant's platelet count. Participants will have regular blood tests and clinical assessments to monitor platelet levels, bleeding episodes, and treatment safety.
Biological: Mini-Pool IVIG
Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated, closed-system process. Each participant will receive a loading dose of 1 g/kg infused intravenously over 6-8 hours. Maintenance doses of 0.5 g/kg will be given every 2 to 4 weeks for up to five additional doses, with the dosing schedule adjusted based on platelet count. The preparation contains purified IgG and meets safety standards for sterility and viral inactivation.
Bleeding Frequency and Severity
Number, location, and severity of bleeding episodes assessed using the Bleeding assessed using the ISTH Bleeding Assessment Tool (BAT) score, which evaluates bleeding symptoms across multiple anatomical sites. Each site is scored from 0 to 4, with higher scores indicating more severe bleeding. The total score varies depending on the number and severity of bleeding events.Assessment Tool (BAT) score.
Time frame: From enrollment through 6 months post-treatment.
Platelet Count Response
Number of participants achieving complete response (platelet count ≥100×10⁹/L) or response (platelet count ≥30×10⁹/L and at least 2-fold increase from baseline) without bleeding.
Time frame: Assessed monthly during treatment and for 6 months after last dose.
Frequency of Hospital Admissions Due to Critical Bleeding
Number of hospital admissions for life-threatening bleeding episodes, excluding admissions solely for IVIG infusion.
Time frame: From enrollment through 6 months post-treatment.
Adverse Events
Number and type of infusion-related or delayed adverse events experienced during or after mini-pool IVIG treatment.
Time frame: From first infusion through 6 months after the last dose.
School Attendance
Change in days missed from school compared to baseline, as a measure of quality of life.
Time frame: From enrollment through 6 months post-treatment.
Patient and Family Satisfaction
Level of satisfaction with mini-pool IVIG treatment as reported by participants and caregivers using a structured satisfaction questionnaire.
Time frame: Assessed at the end of treatment and at 6-month follow-up.
Sustained Response Off-Therapy (SRoT/RoT)
number of participants maintaining platelet counts ≥100×10⁹/L (SRoT) or ≥30×10⁹/L without bleeding (RoT) for at least 6 months after completing mini-pool IVIG therapy.
Time frame: 6 months after last mini-pool IVIG dose.
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →